Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
286
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
-390K
-
Total reported value, excl. options
-
$4.24B
-
Value change
-
-$31M
-
Put/Call ratio
-
0.26
-
Number of buys
-
127
-
Number of sells
-
-144
-
Price
-
$85.14
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2023
336 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q2 2023.
HAEMONETICS CORP - Common Stock (HAE) has 286 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.69M shares), BlackRock Inc. (5.81M shares), VANGUARD GROUP INC (5.35M shares), NEUBERGER BERMAN GROUP LLC (3.57M shares), WELLINGTON MANAGEMENT GROUP LLP (3.22M shares), FMR LLC (2.04M shares), STATE STREET CORP (1.75M shares), FRANKLIN RESOURCES INC (1.64M shares), SCHRODER INVESTMENT MANAGEMENT GROUP (996K shares), and GEODE CAPITAL MANAGEMENT, LLC (991K shares).
This table shows the top 286 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.